

May 09, 2025

To,  
National Stock Exchange of India Ltd.  
Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai-400 051  
**Symbol: JLHL**

To,  
BSE Limited  
P. J. Towers,  
25<sup>th</sup> Floor, Dalal Street, Fort  
Mumbai 400 001  
**Code: 543980**

**Subject: Investor Presentation for the quarter and year ended March 31, 2025**

**Reference: Unaudited Financial Results for the quarter ended March 31, 2025 and Audited Financial Results of the Company for the financial year ended March 31, 2025 (both Standalone and Consolidated)**

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited Financial Results for the quarter ended March 31, 2025 and Audited Financial Results of the Company for the financial year ended March 31, 2025 (both Standalone and Consolidated).

The same will be available on the website of the Company at [www.jupiterhospital.com](http://www.jupiterhospital.com).

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you.

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti  
Company Secretary & Compliance Officer

Encl.: As stated above.



**Bringing **care** into Healthcare.**

**Results Presentation**  
**Q4 & FY25**





This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



## Patient First






**Dr. Ankit Thakker ED & CEO**

*“We now have visibility into a 2,500-bed network in our target region of Western India. The 500-bed Dombivli hospital is expected to launch as planned in Q1FY27. The second Pune hospital, also with 500 beds, has received all building permissions and environmental clearances. Excavation work has commenced, and construction is expected to begin after the monsoon this year. The land at Mira Road has been acquired; this will be our third hospital in the MMR. We plan to construct a 300-bed hospital there.*

*In FY25, significant infrastructure upgrades were implemented at our Thane hospital through departmental restructuring. In Indore, we operationalised 78 additional beds starting January 1, 2025. Additionally, 11 ICU beds have been prepared for commissioning based on demand, enabling scalable critical care services.*

*Looking ahead, our focus remains on executing these projects with superior, patient-centric infrastructure and delivering best-in-class care to our patients.”*

# Key Performance Highlights of FY25



\*Adjusted for Deposit paid on Lease in FY24    #Including Investment

# Key Highlights of FY25

01

Thane Hospital has undergone departmental restructuring, with the 22-bed economy ward discontinued to accommodate two new OT's, a Cath Lab, an upgraded and expanded MRI facility, the expansion of a daycare department, various engineering works, and the ongoing construction of OPDS

02

- At Indore Hospital, 78 additional beds became operational on January 1, 2025
- An 11-bed ICU has been prepared for commissioning and will be activated based on occupancy requirements

03


- Dombivli Hospital incurred a capital expenditure of Rs. 85 cr in FY25
- Total expenditure to date, including land acquisition Rs. 165 cr

04

Pune II Hospital has received environmental clearance. Excavation work is underway, and construction is expected to commence after the upcoming monsoon season

# FY25 Performance Highlights

Rs in Cr




PAT for FY24 includes a benefit of deferred tax charge of Rs. 34.1 Cr

# FY25 Operating Metrics




## Operational Bed Capacity<sup>(1)</sup>


Census Beds    Non - Census Beds




## Average Occupancy Rate<sup>(2)</sup>




## IPD & OPD Volumes ('000)<sup>(3)</sup>



## ARPOB<sup>(4)</sup>




## ALOS (in Days)<sup>(5)</sup>



## Payor Mix

Government Schemes    Self Payors    Insurance Companies



ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.



# Strategic Financial Positioning of JLHL & JHPPL

Entity	Cash Position*	Debt	Net Cash / (Debt)	Remarks
Jupiter Life Line Hospital Limited	Rs. 602 cr	Rs 75 cr	Rs 527 cr	Sanctioned loan of Rs 350cr and availed Rs 75 cr for capex
Jupiter Hospital Projects Pvt. Ltd.	Rs. 1 cr	Rs 250 cr	(Rs. 250 cr)	JHPPL secured a debt of Rs 250 cr to repay the loan taken from the parent entity
<b>Total</b>	<b>Rs. 603 cr</b>	<b>Rs 325 cr</b>	<b>Rs 277 cr</b>	Cash available to fund future expansion

***Strong Cash Position at Standalone Entity to pursue new opportunities for expansion of the hospital network***

## Resulting Financial Advantage

- Improved capital recycling
- Strong reserve buffer
- Positioning for expansion

# Consolidated Profit & Loss Statement

Profit and Loss (in Rs. Cr)	Q4FY25	Q4FY24	YoY	FY25	FY24	YoY
<b>Revenue from Operations</b>	<b>323.1</b>	<b>288.2</b>	<b>12.1%</b>	<b>1,245.4</b>	<b>1,059.8</b>	<b>17.5%</b>
Other Income - Operational	3.7	3.2		16.1	13.6	
<b>Total Income</b>	<b>326.7</b>	<b>291.4</b>	<b>12.1%</b>	<b>1,261.5</b>	<b>1,073.4</b>	<b>17.5%</b>
Cost of Goods Sold	61.1	52.8		230.2	189.5	
<b>Gross Profit</b>	<b>265.6</b>	<b>238.6</b>	<b>11.3%</b>	<b>1,031.4</b>	<b>884.0</b>	<b>16.7%</b>
<b>Gross Profit Margin</b>	<b>81.3%</b>	<b>81.9%</b>		<b>81.8%</b>	<b>82.3%</b>	
Employee Cost	53.8	51.5		214.5	189.9	
Professional Fees	81.2	71.7		312.1	271.4	
Other Expenses	52.3	52.2		208.2	180.6	
<b>EBITDA</b>	<b>78.3</b>	<b>63.2</b>	<b>23.9%</b>	<b>296.6</b>	<b>242.1</b>	<b>22.5%</b>
<b>EBITDA Margin</b>	<b>23.9%</b>	<b>21.7%</b>		<b>23.5%</b>	<b>22.6%</b>	
Depreciation	17.6	10.4		57.0	42.4	
<b>EBIT</b>	<b>60.6</b>	<b>52.8</b>	<b>14.9%</b>	<b>239.6</b>	<b>199.7</b>	<b>20.0%</b>
<b>EBIT Margin</b>	<b>18.6%</b>	<b>18.1%</b>		<b>19.0%</b>	<b>18.6%</b>	
Other Income - Finance	7.0	8.1		28.7	22.0	
Finance Cost	5.6	0.9		10.6	26.3	
Exceptional Item Gain / (Loss)	0.0	2.3		0.0	0.0	
<b>PBT</b>	<b>62.1</b>	<b>62.2</b>	<b>-0.2%</b>	<b>257.7</b>	<b>195.4</b>	<b>31.9%</b>
<b>PBT Margin</b>	<b>19.0%</b>	<b>21.3%</b>		<b>20.4%</b>	<b>18.2%</b>	
Tax	17.2	16.9		64.2	18.8	
<b>PAT<sup>#</sup></b>	<b>44.9</b>	<b>45.3</b>	<b>-0.9%</b>	<b>193.5</b>	<b>176.6</b>	<b>9.6%</b>
<b>PAT Margin</b>	<b>13.7%</b>	<b>15.5%</b>		<b>15.3%</b>	<b>16.5%</b>	
Basic EPS	6.84	6.49		29.47	28.44	

- Higher depreciation arising from the addition of newer beds / Facility Expansion, and also includes depreciation on the Right to use assets
- Increase in finance costs on account of the overall increase in gross debt for the ongoing capex plan and Interest cost of Right to Use asset for Leasehold land

# Consolidated Balance Sheet



Equity & Liabilities (in Rs. Cr)	Mar-25	Mar-24
<b>Total Equity</b>	<b>1,356.2</b>	<b>1,168.7</b>
Share Capital	65.6	65.6
Other Equity	1,290.7	1,103.5
Minority Interest	0.0	-0.3
<b>Non-Current Liabilities</b>	<b>396.2</b>	<b>6.8</b>
<b>Financial Liabilities</b>		
Borrowings	321.7	-
Lease liabilities	62.3	-
Deferred Tax Liabilities	7.1	3.7
Other non current liabilities	0.0	-
Provisions	5.0	3.1
<b>Current Liabilities</b>	<b>152.4</b>	<b>105.8</b>
<b>Financial Liabilities</b>		
Borrowings	4.0	-
Lease liabilities	5.1	-
Trade Payables	102.9	62.2
Other Current Liabilities	24.8	22.7
Current tax liabilities (net)	0.3	2.2
Provisions	15.4	18.6
<b>Total Equity &amp; Liabilities</b>	<b>1,904.9</b>	<b>1,281.3</b>

Assets (in Rs. Cr)	Mar-25	Mar-24
<b>Non - Current Assets</b>	<b>1,217.8</b>	<b>871.6</b>
Property Plant & Equipments	898.8	715.5
Right of use assets	74.0	-
CWIP	185.1	74.0
Other Intangible assets	4.6	2.1
<b>Financial Assets</b>		
Investments	0.1	0.1
Other Financial Assets	54.7	78.9
Other Non - Current Assets (Net)	0.5	0.9
<b>Current Assets</b>	<b>687.1</b>	<b>409.8</b>
Inventories	24.1	21.3
<b>Financial Assets</b>		
Investments	114.3	16.9
Trade receivables	41.9	57.2
Cash and cash equivalents	368.3	23.0
Bank balances other than above	120.3	278.2
Other financial assets	0.4	0.6
Other Current Assets	17.7	12.5
<b>Total Assets</b>	<b>1,904.9</b>	<b>1,281.3</b>

# Consolidated Cash Flow Statement



Profit and Loss (in Rs. Cr)	Mar-25	Mar-24
<b>Net Profit Before Tax</b>	<b>257.7</b>	<b>195.4</b>
Adjustments for: Non -Cash Items / Other Investment or Financial Items	43.0	49.7
<b>Operating profit before working capital changes</b>	<b>300.7</b>	<b>245.1</b>
Changes in working capital	20.0	-80.9
<b>Cash generated from Operations</b>	<b>320.7</b>	<b>164.2</b>
Direct taxes paid (net of refund)	-67.4	-49.7
<b>Net Cash from Operating Activities</b>	<b>253.3</b>	<b>114.5</b>
<b>Net Cash from Investing Activities</b>	<b>-208.6</b>	<b>-246.1</b>
<b>Net Cash from Financing Activities</b>	<b>300.6</b>	<b>128.1</b>
<b>Net Increase/(decrease) in Cash and Cash equivalents</b>	<b>345.3</b>	<b>-3.5</b>
Add: Cash & Cash equivalents at the beginning of the period	23.0	26.5
<b>Cash &amp; Cash equivalents at the end of the period</b>	<b>368.3</b>	<b>23.0</b>

- Dombivli Greenfield Expansion Rs 85 cr
- Brownfield Expansion (Pune I and Indore) of Beds of Rs 40 cr
- Mira-Bhayandar Hospital land acquisition Rs 75 cr

# Scaling up for better care: Setting up New hospital / Bed additions

Location	Existing Hospitals			Upcoming Hospitals			Total
	Thane	Pune I (Baner)	Indore	Dombivli	Pune II (Bibwewadi)	Mira - Bhayandar	
Total Bed Capacity	377	386	431	500	500	300	2,494
Operational Beds	377	375	309	-	-	-	1,061
Expected Bed Addition Phase I	-	11	11*	200-220	200-220	150-170	572-632
Expected Bed Addition Phase II	-	-	111	280-300	280-300	130-150	801-861
Capex Estimated (Rs in cr)	-	2.5	-	500	500	400	1,400-1,600
Expected to Operationalise	-	-	-	Q1FY27	CY28	CY29	

\*Ready for commissioning



***PATIENT FIRST***

## **Jupiter Life Line Hospitals Limited**

CIN: L85100MH2002PLC137908

[investor.relations@jupiterhospital.com](mailto:investor.relations@jupiterhospital.com)

**SGA** Strategic Growth Advisors

## **Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

**Mandar Chavan / Rahul Agarwal**

[mandar.chavan@sgapl.net](mailto:mandar.chavan@sgapl.net) / [rahul.agarwal@sgapl.net](mailto:rahul.agarwal@sgapl.net)

+91 96993 82195 / +91 98214 38864